Daniel D. Mikol

7.2k total citations · 3 hit papers
93 papers, 4.9k citations indexed

About

Daniel D. Mikol is a scholar working on Psychiatry and Mental health, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, Daniel D. Mikol has authored 93 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Psychiatry and Mental health, 51 papers in Pathology and Forensic Medicine and 14 papers in Molecular Biology. Recurrent topics in Daniel D. Mikol's work include Migraine and Headache Studies (55 papers), Trigeminal Neuralgia and Treatments (31 papers) and Multiple Sclerosis Research Studies (16 papers). Daniel D. Mikol is often cited by papers focused on Migraine and Headache Studies (55 papers), Trigeminal Neuralgia and Treatments (31 papers) and Multiple Sclerosis Research Studies (16 papers). Daniel D. Mikol collaborates with scholars based in United States, Germany and Switzerland. Daniel D. Mikol's co-authors include Robert Lenz, Uwe Reuter, Messoud Ashina, Hernàn Picard, Jan Lewis Brandes, Stewart J. Tepper, Peter J. Goadsby, Sunfa Cheng, Stephen D. Silberstein and Feng Zhang and has published in prestigious journals such as New England Journal of Medicine, Analytical Chemistry and Neurology.

In The Last Decade

Daniel D. Mikol

90 papers receiving 4.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Controlled Trial of Erenumab for Episodic Migraine

2017 631 citations Peter J. Goadsby, Uwe Reuter et al. New England Journal of Medicine profile →
Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial

2017 538 citations Stewart J. Tepper, Messoud Ashina et al. profile →
ARISE: A Phase 3 randomized trial of erenumab for episodic migraine

2018 423 citations David W. Dodick, Messoud Ashina et al. Cephalalgia profile →

Peers

Countries citing papers authored by Daniel D. Mikol

Since Specialization

Citations

This map shows the geographic impact of Daniel D. Mikol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel D. Mikol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel D. Mikol more than expected).

Fields of papers citing papers by Daniel D. Mikol

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel D. Mikol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel D. Mikol. The network helps show where Daniel D. Mikol may publish in the future.

Co-authorship network of co-authors of Daniel D. Mikol

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel D. Mikol. A scholar is included among the top collaborators of Daniel D. Mikol based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel D. Mikol. Daniel D. Mikol is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	NVG-291 Phase 1 Results and Phase 1b/2a Study Design in Individuals with Spinal Cord Injury 2024 ·Archives of Physical Medicine and Rehabilitation ·Daniel D. Mikol, Judy Toews, (unknown), Marc A. DePaul, (unknown), James D. Guest, Mónica A. Pérez	1
2	Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine 2024 ·JAMA Neurology ·Stewart J. Tepper, David W. Dodick, Michel Lantéri‐Minet, David Doležil, Raquel Gil‐Gouveia, Christian Lucas, Karolina Piasecka‐Stryczynska, Gyöngyi Szabó, Daniel D. Mikol, (unknown), Denise E. Chou, Yiping Yang, Gabriel Paiva da Silva Lima	7
3	Long‐term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis 2023 ·Headache The Journal of Head and Face Pain ·Stewart J. Tepper, Richard B. Lipton, Stephen D. Silberstein, David Kudrow, Messoud Ashina, Uwe Reuter, David W. Dodick, Andrea Wang, Sunfa Cheng, Jan Klatt, Daniel D. Mikol	5
4	Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studies 2021 ·Cephalalgia ·Richard B. Lipton, David W. Dodick, David Kudrow, Uwe Reuter, Nadia Tenenbaum, Feng Zhang, Gabriel Paiva da Silva Lima, Denise E. Chou, Daniel D. Mikol	4
5	Migraine Polygenic Risk Score Is Associated with Severity of Migraine – Analysis of Genotypic Data from Four Placebo-controlled Trials of Erenumab (1214) 2020 ·Neurology ·Daniel D. Mikol, Hernàn Picard, Jan Klatt, Andrea Wang, (unknown), Hreinn Stefánsson	1
6	Efficacy and safety of erenumab in women with a history of menstrual migraine 2020 ·The Journal of Headache and Pain ·Jelena Pavlović, Koen Paemeleire, Hartmut Göbel, Jo Bonner, Alan M. Rapoport, Risa Kagan, Feng Zhang, Hernàn Picard, Daniel D. Mikol	30
7	Sustained Efficacy and Long-term Safety of Erenumab in Patients with Episodic Migraine: 4+ Year Results of a 5-year, Open-label Treatment Period (1203) 2020 ·Neurology ·Messoud Ashina, Peter J. Goadsby, Uwe Reuter, Stephen D. Silberstein, David W. Dodick, Fei Xue, (unknown), Sunfa Cheng, Daniel D. Mikol	5
8	Efficacy of Erenumab in Chronic Migraine Patients with Medication Overuse and Prior Preventive Treatment Failure (S38.002) 2019 ·Neurology ·David W. Dodick, Stewart J. Tepper, Hans‐Christoph Diener, Cristina Tassorelli, Sylvia Lucas, Stefan Evers, Feng Zhang, Denise E. Chou, Nadia Tenenbaum, Jan Klatt, Daniel D. Mikol, Gabriel Paiva da Silva Lima	2
9	A Multi-Center, Open-Label, Pharmacokinetic Drug Interaction Study of Erenumab and a Combined Oral Contraceptive in Healthy Females 2019 ·CNS Drugs ·Yang Xu, (unknown), Yi Wang, Yanchen Zhou, (unknown), (unknown), Daniel D. Mikol, Edward Lee	9
10	Erenumab Immunogenicity: a Pooled Analysis of Phase 2 and Phase 3 Migraine Prevention Clinical Trials (P4.098) 2018 ·Neurology ·Bert B. Vargas, Amaal J. Starling, Stephen D. Silberstein, Yanchen Zhou, Marie‐Louise Trotman, Fei Xue, (unknown), Hernàn Picard, Daniel D. Mikol	5
11	Efficacy of Erenumab For the Treatment of Patients with Episodic Migraine with Aura (P4.094) 2018 ·Neurology ·Peter McAllister, (unknown), (unknown), Lawrence C. Newman, Cristina Tassorelli, Feng Zhang, Hernàn Picard, Daniel D. Mikol	3
12	Erenumab Safety Among Migraine Patients Using Triptans or With Cardiovascular (CV) Risk Factors (P4.100) 2018 ·Neurology ·Paul Winner, Uwe Reuter, David W. Dodick, David Kudrow, J Rózniecki, Fei Xue, (unknown), Sunfa Cheng, Hernàn Picard, Daniel D. Mikol	1
13	Efficacy of erenumab in subjects with episodic migraine with prior preventive treatment failure(s) 2017 ·Ghent University Academic Bibliography (Ghent University) ·Peter J. Goadsby, Koen Paemeleire, Gregor Broessner, Jan Lewis Brandes, Jan Klatt, Feng Zhang, Hernàn Picard, Daniel D. Mikol, Robert Lenz	8
14	A Controlled Trial of Erenumab for Episodic Migraine breakdown → 2017 ·New England Journal of Medicine ·Peter J. Goadsby, Uwe Reuter, Yngve Hallström, Gregor Broessner, Jo Bonner, Feng Zhang, Sandhya Sapra, Hernàn Picard, Daniel D. Mikol, Robert Lenz	631
15	ATON: Results from a Phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritis 2015 ·Journal of the Neurological Sciences ·Robert C. Sergott, Jeffrey L. Bennett, Peter Rieckmann, Xavier Montalbán, Daniel D. Mikol, Ulrich Freudensprung, Thomas Plitz, Johan van Beek	66
16	Rationale for EDSS-Plus, the Primary Composite Endpoint of Disability Progression in the ASCEND Phase 3 Study of Natalizumab for Secondary Progressive Multiple Sclerosis: A Post Hoc Analysis of IMPACT Study Data (P7.240) 2015 ·Neurology ·Daniel D. Mikol, J. A. Cohen, Mark Freedman, Myla Goldman, Hans‐Peter Hartung, Eva Havrdová, Douglas Jeffery, Raj Kapoor, Aaron Miller, Finn Sellebjerg, (unknown), Sophia Lee, Diego Cadavid	1
17	Gray Matter Volume Correlates with Information Processing as Measured by the Symbol Digit Modalities Test (SDMT) but Not with Physical Disability as Measured by the Expanded Disability Status Scale (EDSS) in Patients with Secondary Progressive Multiple Sclerosis (SPMS): Analysis of Baseline Correlations from the ASCEND Natalizumab Study (P6.143) 2015 ·Neurology ·Raj Kapoor, Douglas L. Arnold, Aaron Miller, Mark Freedman, Myla Goldman, Hans‐Peter Hartung, Eva Havrdová, Douglas Jeffery, Finn Sellebjerg, Carmen Castrillo‐Viguera, Yun Chen, Diego Cadavid, Daniel D. Mikol	0
18	Caveolin-1 expression in Schwann cells 2006 ·Deep Blue (University of Michigan) ·Daniel D. Mikol, (unknown), Hsin-Lin Cheng, Eva L. Feldman	45
19	Serum IgE reactive against small myelin protein-derived peptides is increased in multiple sclerosis patients 2006 ·Journal of Neuroimmunology ·Daniel D. Mikol, Charles Ditlow, (unknown), Pinaki Biswas, J. G. Kalbfleisch, Andrew Milner, Emanuel Calenoff	18
20	Oligodendrocyte‐myelin glycoprotein is present in lipid rafts and caveolin‐1‐enriched membranes 2005 ·Glia ·Madanamohan Boyanapalli, (unknown), Oscar Lahoud, (unknown), Peter E. Braun, Daniel D. Mikol	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact